The Technion‑Israel Institute of Technology has seen a significant breakthrough in cancer research, with two of its faculties collaborating to develop a novel compound that effectively targets aggressive tumor cells.
Targeting Treatment‑Resistant Tumors
Researchers led by Dr. Avital Oknin Vaisman and Dr. Deepanjan Panda from the Technion have published a study in Oncogene, presenting a new strategy to combat aggressive cancers like bone tumors and melanoma, which typically do not respond to molecular therapies.
The effort was coordinated across the Rappaport Center for Cancer Research, where Prof. Amir Orian provides strategic direction, and the Schulich Faculty of Chemistry, headed by Prof. Ashraf Brik. This interdisciplinary partnership brought together expertise in medicinal chemistry, molecular biology, and oncology, creating a fertile environment for the design of a molecule that attacks cancer on two fronts simultaneously.
A New Class of Molecules
The team developed a new class of molecules called R4VPs, belonging to a group of compounds known as PROTACs, or PROtein TArgeting Chimeras/Degraders. Unlike traditional inhibitors that block protein activity, PROTACs induce the degradation of target proteins through the ubiquitin pathway, offering a pioneering approach to targeting molecular drivers of cancer.
Within the PROTAC family, the R4VPs stand out because they incorporate two distinct targeting modules in a single scaffold. One module engages the E3 ligase RNF4, a protein that safeguards the stability of many oncoproteins that cancer cells rely on for unchecked growth. The second module captures the VHL E3 ligase, an enzyme that normally suppresses ferroptosis, a lethal form of iron‑dependent cell death. By pulling both proteins into the ubiquitin machinery, the compound triggers a rapid collapse of the cancer cell’s protective network.
The Technion researchers have developed the first dual‑targeting PROTAC that simultaneously degrades the enzyme RNF4, key for the stability of oncoproteins, and VHL, an enzyme that prevents a form of programmed cell death known as ferroptosis. Exposure to these compounds kills cancer cells within hours.
Crucially, these compounds demonstrate remarkable selectivity, targeting cancer cells almost exclusively and sparing healthy cells, which could significantly reduce the side effects associated with chemotherapy.
Related: OPTAR Expands into New Drug Targets
Beyond the core chemical architecture, the scientists refined the pharmacokinetic properties of the R4VPs to enhance cellular uptake and ensure that the degrader reaches intracellular compartments where RNF4 and VHL reside. This optimization involved iterative synthesis cycles guided by structural insights from both the chemistry and biology teams.
Promising Results and Future Directions
The study shows this intervention to be particularly effective against cancer cells resistant to existing therapies, as well as various types of bone cancer cells isolated directly from patients’ tumors during surgery. However, further studies in mouse models and clinical trials in humans are necessary to evaluate safety and efficacy before this approach can be applied in medical practice.
In the middle of this exciting development, it’s worth pausing to consider the potential impact on cancer patients. For those with aggressive cancers, who often face limited treatment options and grim prognoses, the promise of a new, targeted therapy that spares healthy cells is nothing short of transformative. It offers hope for improved survival rates and a better quality of life.
The research was supported by several organizations, including the Israel Innovation Authority, the Rappaport Institute for Research in the Medical Sciences, and the German‑Israeli Project Cooperation Foundation. The study involved researchers from the Helmholtz Munich Research Center and Goethe University Frankfurt, as well as various research groups at the Technion.
Additional financial backing came from the Flinkman Family Cancer Research Fund and the Israel Cancer Research Fund, reflecting a broad coalition of public and private stakeholders eager to advance precision oncology. The inclusion of the KAMIN Grant from the Israel Innovation Authority shows the national priority placed on translating cutting‑edge science into therapeutic options.
Collaboration with the Helmholtz Munich team, led by Prof. Markus Diefenbacher, provided access to advanced proteomics platforms that confirmed the simultaneous depletion of RNF4 and VHL in treated cells. Parallel work with Prof. Torsten Mosler at Goethe University supplied complementary expertise in ferroptosis assays, verifying that the loss of VHL indeed unleashes the iron‑driven cell‑death cascade.
By integrating chemical synthesis, molecular genetics, and in‑depth biochemical validation, the project establishes a blueprint for future dual‑degrader designs. The authors emphasize that this strategy could be adapted to other malignancies where resistance stems from the co‑existence of oncoprotein dependence and evasion of ferroptosis, opening a path toward a new generation of precision medicines.
